ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1351	National Cancer Institute	Html	en	Osteosarcoma and Malignant Fibrous Histiocytoma of Bone Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of osteosarcoma and malignant fibrous histiocytoma of bone.	high-grade osteosarcoma patients 0.629145 co-operative German-Austrian-Swiss osteosarcoma 0.55607 neoadjuvant cooperative osteosarcoma 0.624122 pediatric osteosarcoma 0.57965 locally recurrent osteosarcoma 0.5543 Primary high-grade osteosarcoma 0.612176 parosteal osteosarcoma 0.568181 conventional osteosarcoma 0.56726 High grade osteosarcoma 0.599621 cooperative osteosarcoma study 0.792783 nonmetastatic osteosarcoma 0.60813 german-austrian-swiss osteosarcoma study 0.647756 high-grade osteosarcoma 0.738641 craniofacial osteosarcoma 0.630712 conventional high-grade osteosarcoma 0.570688 patients 0.646684 radiation-associated craniofacial osteosarcoma 0.580431 European Osteosarcoma Intergroup 0.58771 osteosarcoma incidence rate 0.594537 neoadjuvant chemotherapy 0.670909 high-grade extremity osteosarcoma 0.5876 Extraskeletal osteosarcoma 0.568579 Craniofacial osteosarcoma Experience 0.589537 Group Osteosarcoma Study 0.569569 radiation-related osteosarcoma 0.565185	osteosarcoma skip metastases 0.57865 synchronous multifocal osteosarcoma 0.617106 Osteosarcoma Intergroup study 0.567726 et al. 0.76197 PUBMED Abstract 0.575849 unresectable high-grade osteosarcoma 0.562489 primary osteosarcoma 0.586929 periosteal osteosarcoma 0.560798 osteosarcoma study group 0.793978 recurrent osteosarcoma 0.571668 non-metastatic osteosarcoma 0.633808 multi-institutional osteosarcoma study 0.604239 extremity osteosarcoma 0.634474 metastatic osteosarcoma 0.602383 multiinstitutional osteosarcoma study 0.587612 Abstract 0.808529 Clin Oncol 0.842874 operable osteosarcoma 0.589711 cooperative german-austrian-swiss osteosarcoma 0.615008 primary tumor 0.561916 intermediate-grade osteosarcoma 0.59029 Oncology Group 0.566747 cancer 0.596697 osteosarcoma 0.959056	CLICK HERE
1431	National Cancer Institute	Html	en	Prostate Cancer Prevention (PDQ®)–Patient Version	Expert-reviewed information summary about factors that may influence the risk of developing prostate cancer and about research aimed at the prevention of this disease.	cancer risk factors 0.382888 cancer treatment 0.345379 cancer prevention trials 0.393424 prostate cancer prevention 0.528023 cancer protective factor 0.370188 prostate gland 0.401353 Prostate Cancer Events 0.438643 protective factors 0.37428 Cancer Information Service 0.363767 following PDQ summaries 0.363098 PDQ cancer information 0.439164 advanced prostate cancer 0.435515 high-grade prostate cancer 0.447263 Clinical Trials section 0.34275 prevention clinical trials 0.365763 male sex 0.35549 white men 0.343088 men 0.418793 Prevention Editorial Board 0.367822 treatment clinical trials 0.342421 National Cancer Institute 0.410797 clinical trials 0.465084 folic acid 0.367544	cancer information summary 0.404534 fewer prostate cancers 0.434955 Vitamin E Cancer 0.36527 new treatment 0.346999 localized prostate cancer 0.435368 breast cancer prevention 0.361722 Cancer Prevention Trial 0.41435 prostate cancer increases 0.444676 prostate cancer risk 0.48237 cancer patients 0.343751 Cancer Care page 0.358977 cancer risk factor 0.385548 NCI’s PDQ 0.343309 normal prostate growth 0.414243 PDQ summary 0.356651 aggressive prostate cancers 0.429295 NCI PDQ cancer 0.383175 prostate cancer 0.982122 bigger prostate 0.40149 cancer clinical trials 0.368698 risk factors 0.422068 cancer information summaries 0.367063 comprehensive cancer information 0.367142	CLICK HERE
1587	National Cancer Institute	Html	en	Childhood Rhabdomyosarcoma Treatment (PDQ®)–Patient Version	Treatment of children with rhabdomyosarcoma often includes chemotherapy, radiation therapy, and surgery. Learn about the signs, tests to diagnose, survival, treatment, and clinical trials for children with rhabdomyosarcoma in this expert-reviewed summary.	cancer treatment 0.508808 alveolar tumor 0.397789 tissue 0.446976 body 0.557677 type 0.525643 chemotherapy 0.500597 PDQ cancer information 0.443489 childhood rhabdomyosarcoma 0.648755 stereotaxic radiation therapy 0.400999 embryonal tumor 0.43303 clinical trials 0.703451 rhabdomyosarcoma 0.676649 nearby lymph nodes 0.746635 cancer information summary 0.418411 rhabdomyosarcoma cells 0.404898 clinical trial 0.53997 sentinel lymph node 0.434722 malignant tumor cells 0.470546 body radiation therapy 0.454423 lymph nodes 0.791456 radiation therapy machine 0.400658 radiation therapy 0.98278 beam radiation therapy 0.399186 soft tissue sarcoma 0.440069	treatment 0.729346 wide local excision 0.482565 cancer cells 0.726714 Conformal radiation therapy 0.416835 treatment clinical trials 0.409517 stereotactic body radiation 0.441552 National Cancer Institute 0.429355 spinal cord 0.406531 metastatic rhabdomyosarcoma 0.428908 effects cancer treatment 0.408271 new treatment 0.425898 Intensity-modulated radiation therapy 0.401599 external-beam radiation therapy 0.401022 external radiation therapy 0.507659 primary tumor 0.410338 metastatic tumor 0.420784 Childhood Rhabdomyosarcoma Treatment 0.412835 bone marrow 0.399523 cancer clinical trials 0.406325 interstitial radiation therapy 0.400167 tumor 0.799626 recurrent rhabdomyosarcoma 0.413207 internal radiation therapy 0.435661 cancer 0.935623	CLICK HERE
1608	National Cancer Institute	Html	en	Stomach (Gastric) Cancer Screening (PDQ®)–Patient Version	There is no standard or routine screening test for stomach (gastric) cancer. Stomach (gastric) cancer is not common in the U.S. Learn about tests that have been studied to detect or screen for stomach cancer in this expert-reviewed summary.	PDQ Screening 0.53696 Serum pepsinogen levels 0.476069 cancer treatment 0.489595 better food storage 0.483291 cancer screening methods 0.571194 United States 0.52237 ongoing clinical trials 0.488517 screening tests 0.527906 silver-white metallic compound 0.475608 following PDQ summaries 0.550231 Cancer Information Service 0.528818 PDQ cancer information 0.69988 Prevention Editorial Board 0.538784 treatment clinical trials 0.487954 National Cancer Institute 0.62168 clinical trials 0.622347 PDQ documents 0.494877 test result 0.484679 cancer information summary 0.615581 cancer doctors 0.478532 clinical trial 0.495039 new treatment 0.490527 breast cancer prevention 0.511108	test results 0.482671 risk factors 0.481306 Cancer screening trials 0.577316 false-positive test result 0.478411 cancer patients 0.482925 Cancer Care page 0.515504 PDQ database 0.499197 latest published information 0.490927 PDQ® Screening 0.477124 NCI’s PDQ 0.504099 risk factor 0.478731 PDQ summary 0.519732 cancer symptoms 0.504928 NCI PDQ cancer 0.579122 certain risk factors 0.477251 lower salt intake 0.475762 tests 0.5444 stomach cancer 0.956427 cancer information summaries 0.536975 comprehensive cancer information 0.53624 Upper endoscopy 0.478371 stomach cancer screening 0.661237	CLICK HERE
1636	National Cancer Institute	Html	en	Cartilage (Bovine and Shark) (PDQ®)–Patient Version	Expert-reviewed information summary about the use of bovine and shark cartilage as a treatment for people with cancer. Note: The information in this summary is no longer being updated and is provided for reference purposes only.	cancer treatment 0.483107 human cancer cells 0.399726 cartilage treatment 0.54785 shark cartilage 0.911115 PDQ cancer information 0.489648 Cancer Complementary 0.397259 lung cancer 0.396037 new blood vessels 0.529873 blood vessel growth 0.688109 clinical trials 0.661965 testing bovine cartilage 0.553086 powdered cartilage products 0.528871 bovine cartilage 0.754583 cancer information summary 0.450971 clinical trial 0.545778 patients 0.414137 randomized clinical trial 0.405563 NCI PDQ cancer 0.409125 cancer information database 0.395004 liquid shark cartilage 0.530016 liquid cartilage products 0.569642 powdered shark cartilage 0.613657 cancer information 0.501779 breast cancer cells 0.394321	shark cartilage products 0.633195 laboratory study 0.408409 cartilage products 0.782377 Complementary Therapies Editorial 0.405419 cancer cells 0.530307 Cancer Information Service 0.450397 preclinical studies 0.47111 cartilage product AE–941/Neovastat 0.510074 dietary supplements 0.394341 National Cancer Institute 0.540172 studies 0.47228 alternative medicine 0.440784 pancreatic cancer cells 0.3965 human cartilage 0.495387 PDQ Cartilage 0.50056 shark cartilage product 0.665863 cartilage 0.96677 animal studies 0.448189 standard cancer treatment 0.405448 alternative therapies 0.399716 cancer information summaries 0.395389 powdered cartilage 0.59313 bovine cartilage product 0.523261 cancer 0.811115	CLICK HERE
3519	National Cancer Institute	Html	en	Research Team Members	Information about the different types of experts involved in designing and running a clinical trial.	treatment 0.240173 Typical team members 0.477277 data management 0.339957 records 0.222317 Staff physician 0.322575 concept 0.2227 aspects 0.224933 Institutional Review Board 0.455886 study monitoring 0.329306 Treats patients 0.324814 skills 0.22687 presentation 0.223824 Supervises data collection 0.479065 responsibilities 0.228481 recruitment 0.225467 course 0.246736 health care providers 0.443729 Works 0.240321 audits 0.222243	research nurse 0.569926 final data analysis 0.435286 clinical trial 0.945844 Provides data 0.334954 approval 0.227398 different sites 0.354975 monitoring agencies 0.324055 Assesses 0.227864 Data manager 0.339195 different types 0.351452 Communicates 0.231534 principal investigator 0.901171 person 0.339796 quality assurance 0.332626 Educates staff 0.334468 IRB 0.235474 Designing 0.224461 informed consent process 0.715664 experts 0.226806	CLICK HERE
3851	National Cancer Institute	Html	en	Treating Cancer without Harming the Heart	Researchers from the fields of oncology and cardiology are working to find ways to prevent, manage, and possibly even reverse the cardiovascular side effects of certain cancer therapies.	childhood cancers 0.722954 cardiovascular changes 0.633513 cancer treatment-related cardiotoxicity 0.773654 ischemic heart disease 0.641571 research 0.740587 task force 0.629922 childhood cancer increases 0.668587 cardiac health 0.652664 heart problems 0.663961 heart failure 0.684862 risk factors 0.812151 certain cardiac functions 0.66508 Community Oncology Research 0.635145 ischemic cardiac disease 0.673041 breast cancer patients 0.750275 adult survivors 0.677672 heart 0.763054 breast cancer trial 0.667286 Prevention Trials Research 0.631942 radiation therapy 0.716677 childhood cancer 0.74187 cancer treatments 0.731665 childhood cancer treatments 0.686861 study 0.637136	community oncology 0.686779 cancer treatment—chemotherapy agents 0.673113 cardiac side effects 0.698632 Anderson Cancer Center 0.750363 early cardiac dysfunction 0.678902 new research strategies 0.65852 trastuzumab-related cardiac events 0.724465 Dana-Farber Cancer Institute 0.652906 Community Oncology Cardiotoxicity 0.640076 cardiac risk factors 0.767014 subsequent research agendas 0.636051 cardiac adverse effects 0.710556 MD Anderson Cancer 0.75179 cardiac arrhythmia 0.64223 NCI Community Oncology 0.685131 NCI-supported cardiotoxicity studies 0.649029 breast cancer 0.957268 treatment-induced cardiac disease 0.677462 NCI community-based oncology 0.638369 breast cancer treatments 0.671567 Vanderbilt-Ingram Cancer Center 0.655353 cancer clinical trials 0.814235 underlying cardiovascular risk 0.658241 cardiovascular problems 0.640023	CLICK HERE
3963	National Cancer Institute	Html	es	Tratamiento del cáncer de orofaringe (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del cáncer de orofaringe.	tratamiento.Ciertas formas 0.441948 Neck Cancer 0.50872 siguientes procedimientos 0.637903 corporal estereotáctica 0.73941 estadio iv 0.619806 hormona tiroidea 0.524054 siguientes elementos 0.501559 estadio ii 0.502031 rayos x 0.464154 pequeñas marcas 0.437304 estadio ivc 0.501067 enlace drugs approved 0.605888 orofaringe ayuda 0.523898 aguja fina.Se 0.467807 PDQ Consumo 0.531679	estadio iva 0.502486 vías respiratorias 0.466653 cirujano manipula herramientas 0.481463 pequeñas mejora 0.437701 National Cancer Institute 0.433607 siguientes riesgos 0.427789 Instituto Nacional 0.463265 malla ayuda 0.439384 PDQ Tratamiento 0.485984 Physician Data Query 0.531575 radioterapia hiperfraccionada 0.624557 ganglio linfático mide 0.948968 cáncer.ampliar radioterapia 0.563245 distinta intensidad 0.445146 siguientes sumarios 0.538888	CLICK HERE
4394	National Cancer Institute	Html	null	Blue Ribbon Panel Working Groups	Seven working groups comprised of leading experts from the cancer community have been charged with developing recommendations for the Cancer Moonshot Initiative.			CLICK HERE
16851	National Cancer Institute	Html	es	Sulfato de hidracina (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos sobre el uso del sulfato de hidracina como tratamiento para personas con cáncer. Nota: La información contenida en este sumario ya no se actualiza y se ofrece solo con fines de consulta.	Centro Nacional 0.533358 determinados efectos 0.530508 New Hampshire Avenue 0.523784 siguientes aspectos 0.523737 Drug Administration 0.514799 patients with weight 0.533925 NCI Best Case 0.549835 diagnosed non-small-cell lung 0.536234 Grosvenor M 0.517103 datos bibliográficos pubmed 0.525622 siguientes preguntas 0.515807 Heber D 0.517667 siguientes riesgos 0.519241 Instituto Nacional 0.7207 Su JQ 0.518581 Salud Complementaria 0.556196 Visuals Online 0.516984 siguientes resultados 0.521312 curso estudios 0.529991 complementarias revisa 0.524603	Clin Oncol 0.521025 Physician Data Query 0.597613 Goldberg RM 0.517983 PDQ Sulfato 0.709455 Estados Unidos 0.833671 Chlebowski RT 0.553534 breakdown measured 0.519564 libre uso 0.517176 compañía farmacéutica 0.520309 página manejo 0.515736 ¿El tratamiento 0.532073 Bulcavage L 0.518136 patients with 0.551924 siguientes datos 0.520348 ¿Los beneficios 0.514828 juntos cam 0.514239 Funcionamiento motor 0.518326 Tayek JA 0.519355 Series Program 0.514501 medicina complementaria 0.982503	CLICK HERE